Biogen Key Executives
This section highlights Biogen's key executives, including their titles and compensation details.
Find Contacts at Biogen
(Showing 0 of )
Biogen Earnings
This section highlights Biogen's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-12 | $3.43 | $3.44 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $3.77 | $4.08 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $4.07 | $5.28 |
| Read Transcript | Q1 | 2024 | 2024-06-05 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-13 | $3.16 | $2.95 |
| Read Transcript | Q3 | 2023 | 2023-11-08 | $3.99 | $4.36 |
| Read Transcript | Q2 | 2023 | 2023-07-25 | $3.77 | $4.02 |
| Read Transcript | Q1 | 2023 | 2023-04-25 | $3.28 | $3.40 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
$119.36
Stock Price
$17.47B
Market Cap
7.61K
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Biogen, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B |
| Cost of Revenue | $- | $2.53B | $2.28B | $2.11B | $1.81B |
| Gross Profit | $9.68B | $7.30B | $7.90B | $8.87B | $11.64B |
| Gross Profit Ratio | 100.00% | 74.24% | 77.61% | 80.79% | 86.57% |
| Research and Development Expenses | $2.04B | $2.70B | $2.23B | $2.50B | $3.99B |
| General and Administrative Expenses | $- | $2.43B | $2.35B | $2.58B | $2.39B |
| Selling and Marketing Expenses | $- | $71.40M | $54.10M | $98.70M | $111.80M |
| Selling General and Administrative Expenses | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B |
| Other Expenses | $- | $- | $358.50M | $888.50M | $697.70M |
| Operating Expenses | $4.45B | $6.01B | $4.99B | $6.06B | $7.19B |
| Cost and Expenses | $7.77B | $7.74B | $7.27B | $8.17B | $9.00B |
| Interest Income | $- | $276.50M | $89.30M | $11.00M | $42.00M |
| Interest Expense | $- | $246.90M | $246.60M | $253.60M | $222.50M |
| Depreciation and Amortization | $- | $494.80M | $518.70M | $487.30M | $457.00M |
| EBITDA | $- | $2.38B | $4.36B | $2.49B | $5.73B |
| EBITDA Ratio | 0.00% | 24.17% | 42.83% | 22.64% | 42.62% |
| Operating Income | $5.23B | $2.10B | $2.32B | $2.84B | $4.55B |
| Operating Income Ratio | 54.06% | 21.32% | 22.81% | 25.87% | 33.84% |
| Total Other Income Expenses Net | $-3.32B | $-800.50M | $331.40M | $-1.10B | $497.40M |
| Income Before Tax | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B |
| Income Before Tax Ratio | 19.70% | 13.18% | 35.31% | 15.89% | 37.54% |
| Income Tax Expense | $273.80M | $135.30M | $632.80M | $52.50M | $992.30M |
| Net Income | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B |
| Net Income Ratio | 16.87% | 11.81% | 29.95% | 14.17% | 29.76% |
| EPS | $11.20 | $8.02 | $20.97 | $10.44 | $24.86 |
| EPS Diluted | $11.19 | $7.97 | $20.87 | $10.40 | $24.80 |
| Weighted Average Shares Outstanding | 145.70M | 144.70M | 145.30M | 149.10M | 160.90M |
| Weighted Average Shares Outstanding Diluted | 145.90M | 145.60M | 146.00M | 149.60M | 161.30M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.45B | $2.47B | $2.35B | $2.20B | $2.39B | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | $2.59B | $2.53B | $2.73B | $2.78B | $2.77B | $2.69B | $2.85B | $3.38B | $3.68B | $3.53B |
| Cost of Revenue | $- | $638.70M | $704.80M | $689.80M | $618.30M | $659.60M | $592.70M | $662.80M | $570.90M | $469.50M | $484.00M | $753.90M | $660.10M | $511.80M | $459.70M | $478.10M | $490.60M | $449.10M | $411.10M | $454.30M |
| Gross Profit | $2.45B | $1.83B | $1.65B | $1.51B | $1.77B | $1.87B | $1.86B | $1.80B | $1.97B | $2.04B | $2.11B | $1.78B | $2.07B | $2.27B | $2.32B | $2.22B | $2.36B | $2.93B | $3.27B | $3.08B |
| Gross Profit Ratio | 100.00% | 74.10% | 70.05% | 68.65% | 74.09% | 73.93% | 75.87% | 73.09% | 77.56% | 81.28% | 81.31% | 70.22% | 75.85% | 81.58% | 83.43% | 82.25% | 82.80% | 86.70% | 88.83% | 87.15% |
| Research and Development Expenses | $532.30M | $542.70M | $442.00M | $383.60M | $570.90M | $736.30M | $584.20M | $570.60M | $601.60M | $549.20M | $528.60M | $551.70M | $699.50M | $702.40M | $585.10M | $514.20M | $1.73B | $1.14B | $647.60M | $476.30M |
| General and Administrative Expenses | $- | $- | $- | $- | $537.10M | $- | $548.00M | $- | $578.70M | $- | $572.60M | $- | $689.20M | $- | $- | $- | $694.50M | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $71.40M | $- | $- | $- | $54.10M | $- | $- | $- | $98.70M | $- | $- | $- | $111.80M | $- | $- | $- |
| Selling General and Administrative Expenses | $680.00M | $588.40M | $553.80M | $581.50M | $608.50M | $788.20M | $548.00M | $605.00M | $632.80M | $563.30M | $572.60M | $634.90M | $787.90M | $654.10M | $637.30M | $595.00M | $806.30M | $573.10M | $555.10M | $570.10M |
| Other Expenses | $- | $245.00M | $-2.00M | $-1.90M | $1.60M | $-300.00M | $109.80M | $107.30M | $210.20M | $101.80M | $96.90M | $-50.40M | $-182.10M | $-1.00M | $-3.00M | $100.00K | $683.50M | $-128.60M | $4.20M | $-120.50M |
| Operating Expenses | $1.21B | $1.38B | $995.80M | $965.10M | $1.31B | $1.64B | $1.24B | $1.28B | $1.44B | $1.21B | $1.20B | $1.14B | $1.49B | $1.49B | $1.81B | $1.28B | $2.85B | $1.87B | $1.29B | $1.19B |
| Cost and Expenses | $2.16B | $2.01B | $1.70B | $1.65B | $1.93B | $2.30B | $1.83B | $1.95B | $2.02B | $1.68B | $1.68B | $1.89B | $2.15B | $2.00B | $2.27B | $1.75B | $3.34B | $2.32B | $1.70B | $1.64B |
| Interest Income | $- | $11.60M | $20.10M | $17.40M | $23.80M | $95.90M | $75.90M | $80.90M | $49.90M | $23.90M | $12.60M | $2.90M | $2.80M | $2.60M | $2.70M | $2.90M | $4.00M | $6.00M | $7.60M | $24.40M |
| Interest Expense | $- | $59.80M | $61.30M | $69.20M | $71.50M | $63.80M | $49.10M | $62.50M | $54.80M | $59.90M | $65.80M | $66.10M | $66.30M | $66.30M | $56.40M | $64.70M | $56.00M | $56.30M | $66.00M | $44.30M |
| Depreciation and Amortization | $- | $182.80M | $158.80M | $147.60M | $140.10M | $125.00M | $117.40M | $112.30M | $239.70M | $120.70M | $134.70M | $143.20M | $127.10M | $132.70M | $72.90M | $146.90M | $90.40M | $114.70M | $112.90M | $119.90M |
| EBITDA | $- | $693.60M | $918.80M | $681.60M | $601.20M | $47.60M | $750.70M | $613.10M | $898.30M | $945.40M | $1.47B | $556.70M | $598.40M | $955.00M | $711.40M | $678.60M | $518.40M | $1.17B | $2.10B | $2.01B |
| EBITDA Ratio | 0.00% | 28.13% | 39.05% | 30.98% | 25.19% | 1.88% | 30.57% | 24.89% | 35.31% | 37.69% | 56.78% | 21.99% | 21.89% | 34.37% | 25.64% | 25.19% | 18.17% | 34.72% | 56.97% | 56.88% |
| Operating Income | $1.24B | $496.40M | $652.40M | $545.40M | $291.60M | $-141.20M | $655.70M | $526.90M | $340.10M | $850.30M | $973.10M | $610.70M | $587.10M | $794.00M | $485.70M | $973.90M | $-330.60M | $1.09B | $1.97B | $1.82B |
| Operating Income Ratio | 50.61% | 20.13% | 27.73% | 24.79% | 12.22% | -5.58% | 26.70% | 21.39% | 13.37% | 33.90% | 37.58% | 24.12% | 21.48% | 28.57% | 17.50% | 36.15% | -11.59% | 32.18% | 53.63% | 51.49% |
| Total Other Income Expenses Net | $-950.90M | $-45.40M | $-113.20M | $-80.60M | $-133.60M | $-376.00M | $- | $-79.00M | $75.30M | $444.60M | $265.60M | $-263.30M | $-182.10M | $-502.90M | $96.40M | $-506.90M | $683.50M | $-128.60M | $63.00M | $-120.50M |
| Income Before Tax | $291.50M | $451.00M | $698.70M | $464.80M | $291.60M | $-141.20M | $708.10M | $438.30M | $603.80M | $1.37B | $1.27B | $347.40M | $405.00M | $291.10M | $582.10M | $467.00M | $352.90M | $957.80M | $2.04B | $1.70B |
| Income Before Tax Ratio | 11.88% | 18.29% | 29.69% | 21.12% | 12.22% | -5.58% | 28.83% | 17.80% | 23.73% | 54.66% | 49.03% | 13.72% | 14.81% | 10.48% | 20.98% | 17.33% | 12.37% | 28.37% | 55.34% | 48.08% |
| Income Tax Expense | $24.70M | $62.50M | $115.10M | $71.40M | $42.70M | $-72.90M | $114.80M | $50.70M | $54.30M | $236.20M | $216.70M | $125.60M | $443.20M | $-25.90M | $-409.10M | $44.20M | $13.30M | $240.80M | $446.10M | $292.00M |
| Net Income | $266.80M | $388.50M | $583.60M | $393.40M | $249.70M | $-68.10M | $591.60M | $387.90M | $550.40M | $1.13B | $1.06B | $221.80M | $368.20M | $329.20M | $448.50M | $410.20M | $357.90M | $701.50M | $1.54B | $1.40B |
| Net Income Ratio | 10.87% | 15.76% | 24.80% | 17.88% | 10.46% | -2.69% | 24.09% | 15.75% | 21.64% | 45.23% | 40.86% | 8.76% | 13.47% | 11.85% | 16.16% | 15.23% | 12.55% | 20.78% | 41.89% | 39.59% |
| EPS | $1.83 | $2.67 | $4.01 | $2.71 | $1.72 | $-0.47 | $4.09 | $2.69 | $3.82 | $7.86 | $7.25 | $1.51 | $2.51 | $2.22 | $3.00 | $2.70 | $2.33 | $4.47 | $9.60 | $8.10 |
| EPS Diluted | $1.83 | $2.66 | $4.00 | $2.70 | $1.71 | $-0.47 | $4.07 | $2.67 | $3.79 | $7.84 | $7.24 | $1.50 | $2.50 | $2.22 | $2.99 | $2.69 | $2.32 | $4.46 | $9.59 | $8.08 |
| Weighted Average Shares Outstanding | 145.70M | 145.70M | 145.60M | 145.20M | 144.90M | 144.80M | 144.70M | 144.40M | 144.10M | 144.40M | 145.90M | 147.10M | 146.90M | 148.00M | 149.70M | 151.90M | 153.70M | 156.90M | 160.60M | 172.80M |
| Weighted Average Shares Outstanding Diluted | 145.90M | 145.90M | 145.90M | 145.90M | 145.70M | 144.80M | 145.50M | 145.20M | 145.20M | 144.80M | 146.20M | 147.60M | 147.50M | 148.60M | 150.10M | 152.30M | 154.00M | 157.20M | 160.90M | 173.10M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.38B | $1.05B | $3.42B | $2.26B | $1.33B |
| Short Term Investments | $- | $- | $1.47B | $1.54B | $1.28B |
| Cash and Short Term Investments | $2.38B | $1.05B | $4.89B | $3.80B | $2.61B |
| Net Receivables | $1.40B | $2.10B | $2.14B | $1.96B | $2.33B |
| Inventory | $2.46B | $2.53B | $1.34B | $1.35B | $1.07B |
| Other Current Assets | $1.22B | $1.18B | $1.42B | $740.80M | $881.10M |
| Total Current Assets | $7.46B | $6.86B | $9.79B | $7.86B | $6.89B |
| Property Plant Equipment Net | $3.54B | $3.73B | $3.70B | $3.79B | $3.84B |
| Goodwill | $6.48B | $6.22B | $5.75B | $5.76B | $5.76B |
| Intangible Assets | $9.69B | $8.36B | $1.85B | $2.22B | $3.08B |
| Goodwill and Intangible Assets | $16.17B | $14.58B | $7.60B | $7.98B | $8.85B |
| Long Term Investments | $560.50M | $460.70M | $2.23B | $2.83B | $5.04B |
| Tax Assets | $324.20M | $928.60M | $1.23B | $1.42B | $1.37B |
| Other Non-Current Assets | $- | $284.30M | $- | $- | $-1.37B |
| Total Non-Current Assets | $20.59B | $19.99B | $14.76B | $16.02B | $17.73B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B |
| Account Payables | $424.20M | $403.30M | $491.50M | $589.20M | $454.90M |
| Short Term Debt | $1.75B | $240.30M | $97.20M | $1.09B | $83.20M |
| Tax Payables | $548.30M | $257.40M | $259.90M | $174.70M | $142.00M |
| Deferred Revenue | $- | $3.00M | $-97.20M | $-589.20M | $-83.20M |
| Other Current Liabilities | $2.81B | $2.53B | $2.42B | $2.45B | $3.06B |
| Total Current Liabilities | $5.53B | $3.43B | $3.27B | $4.30B | $3.74B |
| Long Term Debt | $4.88B | $7.19B | $6.61B | $6.60B | $7.83B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-1.03B |
| Deferred Tax Liabilities Non-Current | $190.50M | $641.80M | $334.70M | $694.50M | $1.03B |
| Other Non-Current Liabilities | $732.30M | $781.10M | $944.20M | $1.32B | $1.33B |
| Total Non-Current Liabilities | $5.80B | $8.61B | $7.89B | $8.62B | $10.19B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
| Retained Earnings | $19.26B | $17.63B | $16.47B | $13.91B | $13.98B |
| Accumulated Other Comprehensive Income Loss | $-136.20M | $-153.70M | $-164.90M | $-106.70M | $-299.00M |
| Other Total Stockholders Equity | $-2.41B | $-2.67B | $-2.90B | $-2.91B | $-2.98B |
| Total Stockholders Equity | $16.72B | $14.80B | $13.39B | $10.96B | $10.69B |
| Total Equity | $16.72B | $14.80B | $13.38B | $11.02B | $10.67B |
| Total Liabilities and Stockholders Equity | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B |
| Minority Interest | $- | $- | $-9.50M | $63.50M | $-14.20M |
| Total Liabilities and Total Equity | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B |
| Total Investments | $560.50M | $460.70M | $2.18B | $4.37B | $6.32B |
| Total Debt | $6.63B | $7.34B | $6.61B | $7.60B | $7.83B |
| Net Debt | $4.26B | $6.29B | $3.19B | $5.34B | $6.50B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.38B | $1.70B | $1.91B | $1.07B | $1.05B | $2.29B | $2.62B | $2.90B | $3.42B | $3.68B | $2.65B | $1.75B | $2.26B | $1.54B | $1.74B | $1.22B | $1.33B | $2.22B | $2.38B | $2.59B |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $3.46B | $2.14B | $1.47B | $1.24B | $2.15B | $2.00B | $1.54B | $1.41B | $1.31B | $1.32B | $1.28B | $1.35B | $1.94B | $1.27B |
| Cash and Short Term Investments | $2.38B | $1.70B | $1.91B | $1.07B | $1.05B | $2.29B | $6.08B | $5.04B | $4.89B | $4.91B | $4.80B | $3.75B | $3.80B | $2.96B | $3.05B | $2.54B | $2.61B | $3.58B | $4.33B | $3.86B |
| Net Receivables | $1.40B | $1.99B | $2.08B | $2.00B | $2.10B | $2.21B | $2.12B | $2.03B | $2.14B | $1.98B | $2.00B | $2.02B | $1.96B | $2.12B | $2.11B | $2.22B | $2.33B | $2.55B | $2.57B | $2.60B |
| Inventory | $2.46B | $2.47B | $2.51B | $2.52B | $2.53B | $2.98B | $1.33B | $1.28B | $1.34B | $1.38B | $1.29B | $1.22B | $1.35B | $1.35B | $1.25B | $1.17B | $1.07B | $1.03B | $952.70M | $858.80M |
| Other Current Assets | $1.22B | $674.00M | $615.30M | $1.17B | $1.18B | $974.10M | $895.90M | $1.41B | $1.42B | $1.50B | $1.65B | $927.40M | $740.80M | $736.30M | $767.90M | $786.10M | $881.10M | $683.50M | $638.80M | $683.80M |
| Total Current Assets | $7.46B | $6.83B | $7.11B | $6.76B | $6.86B | $8.45B | $10.43B | $9.76B | $9.79B | $9.77B | $9.74B | $7.92B | $7.86B | $7.16B | $7.18B | $6.72B | $6.89B | $7.84B | $8.49B | $8.01B |
| Property Plant Equipment Net | $3.54B | $3.59B | $3.64B | $3.70B | $3.73B | $3.76B | $3.67B | $3.70B | $3.70B | $3.69B | $3.68B | $3.73B | $3.79B | $3.80B | $3.84B | $3.85B | $3.84B | $3.79B | $3.77B | $3.70B |
| Goodwill | $6.48B | $6.49B | $6.23B | $6.23B | $6.22B | $6.81B | $5.75B | $5.75B | $5.75B | $5.74B | $5.75B | $5.76B | $5.76B | $5.76B | $5.76B | $5.76B | $5.76B | $5.76B | $5.75B | $5.75B |
| Intangible Assets | $9.69B | $9.81B | $8.23B | $8.28B | $8.36B | $7.34B | $1.78B | $1.81B | $1.85B | $2.01B | $2.08B | $2.15B | $2.22B | $2.29B | $2.38B | $2.99B | $3.08B | $3.32B | $3.38B | $3.45B |
| Goodwill and Intangible Assets | $16.17B | $16.29B | $14.46B | $14.51B | $14.58B | $14.15B | $7.53B | $7.57B | $7.60B | $7.75B | $7.82B | $7.91B | $7.98B | $8.05B | $8.15B | $8.75B | $8.85B | $9.08B | $9.13B | $9.20B |
| Long Term Investments | $560.50M | $631.40M | $354.10M | $382.00M | $460.70M | $754.70M | $2.31B | $2.36B | $2.23B | $2.47B | $2.60B | $2.77B | $2.83B | $2.99B | $3.44B | $3.24B | $5.04B | $4.22B | $2.41B | $5.21B |
| Tax Assets | $324.20M | $968.70M | $915.10M | $898.30M | $928.60M | $1.07B | $1.21B | $1.21B | $1.23B | $1.17B | $1.24B | $1.29B | $1.42B | $1.81B | $1.85B | $1.29B | $1.37B | $1.37B | $1.71B | $3.11B |
| Other Non-Current Assets | $- | $- | $327.40M | $315.60M | $284.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.37B | $-1.37B | $- | $-3.11B |
| Total Non-Current Assets | $20.59B | $21.48B | $19.70B | $19.81B | $19.99B | $19.74B | $14.73B | $14.84B | $14.76B | $15.09B | $15.34B | $15.70B | $16.02B | $16.64B | $17.29B | $17.14B | $17.73B | $17.09B | $17.02B | $18.11B |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $28.05B | $28.31B | $26.80B | $26.57B | $26.84B | $28.19B | $25.16B | $24.60B | $24.55B | $24.85B | $25.08B | $23.61B | $23.88B | $23.81B | $24.47B | $23.85B | $24.62B | $24.93B | $25.51B | $26.12B |
| Account Payables | $424.20M | $422.70M | $354.50M | $387.00M | $403.30M | $440.10M | $445.40M | $491.20M | $491.50M | $383.20M | $434.80M | $398.70M | $589.20M | $427.90M | $375.30M | $430.40M | $454.90M | $398.40M | $383.90M | $389.00M |
| Short Term Debt | $- | $1.75B | $- | $250.00M | $240.30M | $500.00M | $- | $- | $97.20M | $- | $999.80M | $999.50M | $1.09B | $998.80M | $- | $- | $83.20M | $- | $- | $1.50B |
| Tax Payables | $548.30M | $499.10M | $281.60M | $231.20M | $257.40M | $243.80M | $260.00M | $235.50M | $259.90M | $237.30M | $284.90M | $317.30M | $174.70M | $234.20M | $230.90M | $143.10M | $142.00M | $119.40M | $576.70M | $310.00M |
| Deferred Revenue | $- | $- | $281.60M | $-250.00M | $2.04B | $243.80M | $- | $- | $-97.20M | $- | $- | $- | $-589.20M | $2.76B | $- | $- | $- | $- | $- | $-389.00M |
| Other Current Liabilities | $4.56B | $2.76B | $2.47B | $2.35B | $2.53B | $3.84B | $2.48B | $2.29B | $2.42B | $3.31B | $3.30B | $2.23B | $2.45B | $2.55B | $2.74B | $2.59B | $3.06B | $3.29B | $2.49B | $2.44B |
| Total Current Liabilities | $5.53B | $5.42B | $3.11B | $3.22B | $3.43B | $5.02B | $3.19B | $3.01B | $3.27B | $3.93B | $5.02B | $3.95B | $4.30B | $4.21B | $3.35B | $3.17B | $3.74B | $3.80B | $3.45B | $4.64B |
| Long Term Debt | $4.88B | $4.90B | $6.66B | $6.70B | $7.19B | $7.22B | $6.59B | $6.61B | $6.61B | $6.63B | $6.55B | $6.59B | $6.60B | $6.62B | $7.63B | $7.65B | $7.83B | $7.83B | $7.84B | $4.86B |
| Deferred Revenue Non-Current | $- | $- | $367.50M | $-777.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.03B | $-1.12B | $- | $-2.72B |
| Deferred Tax Liabilities Non-Current | $190.50M | $882.40M | $590.60M | $658.10M | $641.80M | $728.10M | $143.90M | $251.30M | $334.70M | $328.90M | $480.60M | $571.20M | $694.50M | $774.70M | $918.90M | $966.70M | $1.03B | $1.12B | $1.46B | $2.72B |
| Other Non-Current Liabilities | $732.30M | $744.10M | $556.70M | $777.10M | $781.10M | $747.90M | $776.90M | $935.50M | $944.20M | $1.20B | $1.17B | $1.29B | $1.32B | $1.32B | $1.36B | $1.41B | $1.33B | $1.43B | $1.48B | $1.36B |
| Total Non-Current Liabilities | $5.80B | $6.53B | $7.81B | $8.13B | $8.61B | $8.69B | $7.51B | $7.80B | $7.89B | $8.16B | $8.20B | $8.45B | $8.62B | $8.71B | $9.91B | $10.03B | $10.19B | $10.39B | $10.78B | $8.94B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $11.33B | $11.95B | $10.91B | $11.35B | $12.05B | $13.71B | $10.70B | $10.81B | $11.17B | $12.09B | $13.22B | $12.39B | $12.92B | $12.93B | $13.26B | $13.19B | $13.93B | $14.19B | $14.22B | $13.58B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $63.50M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K | $100.00K |
| Retained Earnings | $- | $18.99B | $18.60B | $18.02B | $17.63B | $17.38B | $17.45B | $16.85B | $16.47B | $15.92B | $14.96B | $14.22B | $13.91B | $13.54B | $13.90B | $13.83B | $13.98B | $13.96B | $14.47B | $15.67B |
| Accumulated Other Comprehensive Income Loss | $-136.20M | $-145.70M | $-146.00M | $-160.50M | $-153.70M | $-159.30M | $-172.80M | $-172.00M | $-164.90M | $-163.60M | $-110.40M | $-115.20M | $-106.70M | $-136.60M | $-171.80M | $-174.30M | $-299.00M | $-225.50M | $-181.00M | $-149.30M |
| Other Total Stockholders Equity | $17.58B | $-2.49B | $-2.57B | $-2.65B | $-2.67B | $-2.73B | $-2.81B | $-2.89B | $-2.90B | $-2.98B | $-2.98B | $-2.86B | $-2.91B | $-2.98B | $-2.98B | $-2.98B | $-2.98B | $-2.98B | $-2.98B | $-2.98B |
| Total Stockholders Equity | $17.45B | $16.36B | $15.89B | $15.21B | $14.80B | $14.48B | $14.46B | $13.79B | $13.39B | $12.78B | $11.86B | $11.22B | $10.96B | $10.43B | $10.75B | $10.68B | $10.69B | $10.74B | $11.31B | $12.54B |
| Total Equity | $17.45B | $16.36B | $15.89B | $15.21B | $14.80B | $14.48B | $14.45B | $13.78B | $13.38B | $12.77B | $11.85B | $11.20B | $11.02B | $10.88B | $11.21B | $10.66B | $10.67B | $10.73B | $11.29B | $12.53B |
| Total Liabilities and Stockholders Equity | $28.05B | $28.31B | $26.80B | $26.57B | $26.84B | $28.19B | $25.16B | $24.60B | $24.55B | $24.85B | $25.08B | $23.61B | $23.88B | $23.81B | $24.47B | $23.85B | $24.62B | $24.93B | $25.51B | $26.12B |
| Minority Interest | $- | $- | $- | $- | $- | $-4.10M | $-6.40M | $-9.60M | $-9.50M | $-8.70M | $-9.10M | $-21.60M | $63.50M | $451.80M | $462.90M | $-19.00M | $-14.20M | $-14.00M | $-19.50M | $-10.00M |
| Total Liabilities and Total Equity | $28.05B | $28.31B | $26.80B | $26.57B | $26.84B | $28.19B | $25.16B | $24.60B | $24.55B | $24.85B | $25.08B | $23.61B | $23.88B | $23.81B | $24.47B | $23.85B | $24.62B | $24.93B | $25.51B | $26.12B |
| Total Investments | $560.50M | $631.40M | $354.10M | $382.00M | $460.70M | $754.70M | $5.77B | $3.12B | $2.18B | $3.71B | $4.75B | $4.77B | $4.37B | $4.40B | $4.75B | $4.56B | $4.95B | $4.20B | $4.35B | $3.37B |
| Total Debt | $4.88B | $6.65B | $6.85B | $6.95B | $7.34B | $7.72B | $6.59B | $6.61B | $6.61B | $6.63B | $7.55B | $7.59B | $7.60B | $7.62B | $7.63B | $7.65B | $7.83B | $7.83B | $7.84B | $6.37B |
| Net Debt | $2.51B | $4.95B | $4.94B | $5.87B | $6.29B | $5.43B | $3.97B | $3.71B | $3.19B | $2.96B | $4.90B | $5.84B | $5.34B | $6.08B | $5.89B | $6.43B | $6.50B | $5.61B | $5.45B | $3.77B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $1.63B | $1.16B | $2.96B | $1.73B | $4.06B |
| Depreciation and Amortization | $673.20M | $494.80M | $518.40M | $487.70M | $457.20M |
| Deferred Income Tax | $-158.10M | $-305.80M | $-168.60M | $-426.80M | $149.00M |
| Stock Based Compensation | $291.20M | $264.20M | $254.10M | $238.60M | $198.30M |
| Change in Working Capital | $-155.20M | $-648.70M | $-890.30M | $-145.50M | $-187.20M |
| Accounts Receivables | $- | $- | $-203.40M | $324.80M | $2.80M |
| Inventory | $- | $- | $-320.20M | $-462.40M | $-316.30M |
| Accounts Payables | $- | $- | $- | $-94.20M | $330.90M |
| Other Working Capital | $-155.20M | $-648.70M | $-366.70M | $86.30M | $-204.60M |
| Other Non Cash Items | $592.20M | $581.20M | $-1.29B | $1.76B | $-448.00M |
| Net Cash Provided by Operating Activities | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B |
| Investments in Property Plant and Equipment | $-153.70M | $277.00M | $-243.20M | $-294.90M | $-551.80M |
| Acquisitions Net | $-668.00M | $-6.14B | $990.30M | $28.10M | $-565.50M |
| Purchases of Investments | $- | $-5.14B | $-3.45B | $-3.81B | $-6.84B |
| Sales Maturities of Investments | $144.70M | $7.50B | $3.67B | $3.50B | $7.37B |
| Other Investing Activities | $-122.20M | $-599.70M | $607.00M | $12.90M | $-26.90M |
| Net Cash Used for Investing Activities | $-799.20M | $-4.10B | $1.58B | $-563.70M | $-608.60M |
| Debt Repayment | $-650.00M | $187.30M | $-1.00B | $-170.00M | $1.47B |
| Common Stock Issued | $- | $-44.30M | $-1.90M | $-700.00K | $-4.60M |
| Common Stock Repurchased | $- | $- | $-750.00M | $-1.80B | $-6.68B |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-33.50M | $-38.00M | $4.90M | $-116.20M | $-61.00M |
| Net Cash Used Provided by Financing Activities | $-683.50M | $149.30M | $-1.76B | $-2.09B | $-5.27B |
| Effect of Forex Changes on Cash | $-67.70M | $35.10M | $-55.70M | $-59.80M | $69.00M |
| Net Change in Cash | $1.33B | $-2.37B | $1.16B | $930.20M | $-1.58B |
| Cash at End of Period | $2.38B | $1.05B | $3.42B | $2.26B | $1.33B |
| Cash at Beginning of Period | $1.05B | $3.42B | $2.26B | $1.33B | $2.91B |
| Operating Cash Flow | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B |
| Capital Expenditure | $-359.80M | $-311.40M | $-243.20M | $-294.90M | $-551.80M |
| Free Cash Flow | $2.52B | $1.24B | $1.14B | $3.35B | $3.68B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $- | $388.50M | $583.60M | $393.40M | $248.90M | $-68.30M | $593.30M | $387.60M | $549.50M | $1.13B | $1.06B | $218.50M | $-20.50M | $318.00M | $1.03B | $404.60M | $357.60M | $703.90M | $1.61B | $1.39B |
| Depreciation and Amortization | $- | $182.80M | $158.80M | $147.60M | $140.10M | $125.00M | $117.40M | $112.30M | $119.80M | $120.70M | $134.80M | $143.10M | $134.70M | $133.20M | $72.90M | $146.90M | $90.40M | $134.00M | $112.90M | $119.90M |
| Deferred Income Tax | $- | $-52.60M | $-87.00M | $39.90M | $71.90M | $-206.80M | $-106.40M | $-64.50M | $-28.80M | $-92.30M | $-48.50M | $1.00M | $323.30M | $-127.30M | $-607.80M | $-15.00M | $-62.90M | $31.70M | $143.30M | $36.90M |
| Stock Based Compensation | $- | $72.70M | $70.60M | $72.80M | $54.90M | $62.20M | $71.50M | $75.60M | $67.20M | $63.60M | $55.70M | $67.60M | $58.80M | $55.70M | $54.10M | $70.00M | $49.00M | $33.50M | $48.10M | $67.70M |
| Change in Working Capital | $- | $417.30M | $-188.60M | $-228.70M | $-648.10M | $314.40M | $-130.90M | $-184.10M | $-987.50M | $-2.70M | $880.40M | $-780.50M | $76.20M | $-116.50M | $226.00M | $-331.20M | $-135.10M | $182.70M | $93.10M | $-327.90M |
| Accounts Receivables | $- | $2.80M | $-87.20M | $84.40M | $137.80M | $-98.30M | $-55.40M | $77.20M | $-93.90M | $-42.20M | $20.20M | $-87.50M | $167.00M | $-53.70M | $174.30M | $37.20M | $138.50M | $133.10M | $-30.40M | $-238.40M |
| Inventory | $- | $188.20M | $-110.50M | $-77.70M | $-96.00M | $30.20M | $-93.00M | $27.90M | $18.10M | $-95.00M | $-100.70M | $-142.60M | $-139.80M | $-128.80M | $-81.30M | $-112.50M | $-45.70M | $-82.40M | $-126.00M | $-62.20M |
| Accounts Payables | $- | $- | $- | $- | $-503.20M | $430.80M | $123.60M | $- | $- | $- | $- | $- | $135.60M | $-32.70M | $42.70M | $-239.80M | $-105.00M | $728.20M | $-23.50M | $-268.80M |
| Other Working Capital | $- | $226.30M | $9.10M | $-235.40M | $-186.70M | $-48.30M | $-106.10M | $-289.20M | $-911.70M | $134.50M | $960.90M | $-550.40M | $-86.60M | $98.70M | $90.30M | $-16.10M | $-122.90M | $-596.20M | $273.00M | $241.50M |
| Other Non Cash Items | $760.90M | $-73.10M | $674.30M | $489.50M | $144.80M | $365.90M | $-57.90M | $128.40M | $104.80M | $-563.20M | $-1.34B | $512.10M | $265.80M | $542.20M | $456.60M | $493.70M | $-666.10M | $95.30M | $-55.30M | $178.10M |
| Net Cash Provided by Operating Activities | $760.90M | $935.60M | $625.80M | $553.20M | $12.50M | $592.40M | $487.00M | $455.30M | $-175.00M | $661.00M | $736.50M | $161.80M | $838.30M | $805.30M | $1.23B | $769.00M | $-367.10M | $1.18B | $1.95B | $1.47B |
| Investments in Property Plant and Equipment | $39.30M | $49.10M | $-42.60M | $-120.90M | $-65.20M | $-87.60M | $-87.00M | $-71.60M | $-87.40M | $-59.10M | $-38.80M | $-57.90M | $-68.50M | $-61.90M | $-71.90M | $-92.60M | $-101.00M | $-84.10M | $-105.00M | $-261.70M |
| Acquisitions Net | $- | $-1.07B | $- | $- | $-590.50M | $-6.34B | $772.10M | $200.00K | $-990.30M | $594.80M | $990.30M | $- | $-28.10M | $-19.90M | $- | $28.10M | $565.50M | $-423.70M | $-141.80M | $-112.00M |
| Purchases of Investments | $- | $- | $- | $- | $- | $-1.02B | $-2.80B | $-1.32B | $-642.60M | $-494.30M | $-1.18B | $-1.13B | $-1.44B | $-745.70M | $-713.60M | $-913.30M | $-2.19B | $-895.20M | $-2.07B | $-1.68B |
| Sales Maturities of Investments | $- | $24.80M | $511.70M | $55.60M | $13.40M | $5.70B | $1.34B | $440.50M | $566.30M | $1.64B | $917.90M | $543.60M | $1.38B | $575.40M | $633.50M | $910.40M | $2.13B | $1.36B | $1.49B | $2.39B |
| Other Investing Activities | $-57.90M | $-180.20M | $-2.60M | $-700.00K | $-10.00M | $-200.00K | $15.60M | $-900.00K | $1.01B | $-12.40M | $2.20M | $-200.00K | $40.40M | $18.50M | $-700.00K | $2.70M | $-574.40M | $-10.20M | $-7.30M | $111.50M |
| Net Cash Used for Investing Activities | $-18.60M | $-1.18B | $466.50M | $-66.00M | $-652.30M | $-1.74B | $-753.50M | $-953.00M | $-141.10M | $1.67B | $693.50M | $-648.00M | $-112.70M | $-233.60M | $-152.70M | $-64.70M | $-166.40M | $-52.40M | $-832.70M | $442.90M |
| Debt Repayment | $- | $- | $-250.00M | $-400.00M | $-650.00M | $837.30M | $- | $- | $- | $-1.00B | $- | $- | $- | $- | $-700.00K | $-169.30M | $100.00K | $- | $1.47B | $- |
| Common Stock Issued | $- | $6.00M | $6.10M | $-46.90M | $3.70M | $6.60M | $5.50M | $-60.10M | $3.90M | $- | $- | $-20.80M | $7.60M | $- | $- | $-27.10M | $- | $- | $- | $-29.60M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $750.00M | $-250.00M | $-500.00M | $- | $1.80B | $-750.00M | $-450.00M | $-600.00M | $-400.00M | $-1.25B | $-2.81B | $-2.22B |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $7.90M | $-12.60M | $-1.30M | $-39.60M | $200.00K | $11.30M | $-9.80M | $16.70M | $-7.40M | $300.00K | $28.50M | $4.30M | $9.80M | $3.50M | $-113.80M | $-15.70M | $-1.20M | $-62.90M | $28.20M | $-25.10M |
| Net Cash Used Provided by Financing Activities | $7.90M | $-6.60M | $-245.20M | $-439.60M | $-646.10M | $848.60M | $-9.80M | $-43.40M | $-7.60M | $-1.26B | $-471.50M | $-16.50M | $9.80M | $-746.50M | $-564.50M | $-785.00M | $-401.10M | $-1.31B | $-1.31B | $-2.25B |
| Effect of Forex Changes on Cash | $- | $42.40M | $-12.60M | $-23.10M | $47.90M | $-28.70M | $-4.10M | $20.00M | $67.20M | $-52.30M | $-61.20M | $-9.40M | $-15.80M | $-25.40M | $14.40M | $-33.00M | $41.00M | $24.10M | $-8.80M | $12.70M |
| Net Change in Cash | $750.20M | $-209.70M | $834.50M | $24.50M | $-1.24B | $-329.90M | $-280.40M | $-521.10M | $-256.30M | $1.03B | $897.30M | $-512.10M | $719.60M | $-200.20M | $524.50M | $-113.70M | $-893.60M | $-160.10M | $-206.40M | $-322.40M |
| Cash at End of Period | $2.38B | $1.70B | $1.91B | $1.07B | $1.05B | $2.29B | $2.62B | $2.90B | $3.42B | $3.68B | $2.65B | $1.75B | $2.26B | $1.54B | $1.74B | $1.22B | $1.33B | $2.22B | $2.38B | $2.59B |
| Cash at Beginning of Period | $1.70B | $1.91B | $1.07B | $1.05B | $2.29B | $2.62B | $2.90B | $3.42B | $3.68B | $2.65B | $1.75B | $2.26B | $1.54B | $1.74B | $1.22B | $1.33B | $2.22B | $2.38B | $2.59B | $2.91B |
| Operating Cash Flow | $760.90M | $935.60M | $625.80M | $553.20M | $12.50M | $592.40M | $487.00M | $455.30M | $-175.00M | $661.00M | $736.50M | $161.80M | $838.30M | $805.30M | $1.23B | $769.00M | $-367.10M | $1.18B | $1.95B | $1.47B |
| Capital Expenditure | $39.30M | $-130.00M | $-42.60M | $-120.90M | $-65.20M | $-87.60M | $-87.00M | $-71.60M | $-87.40M | $-59.10M | $-38.80M | $-57.90M | $-68.50M | $-61.90M | $-71.90M | $-92.60M | $-101.00M | $-84.10M | $-105.00M | $-261.70M |
| Free Cash Flow | $800.20M | $805.60M | $583.20M | $432.30M | $-52.70M | $504.80M | $400.00M | $383.70M | $-262.40M | $601.90M | $697.70M | $103.90M | $769.80M | $743.40M | $1.16B | $676.40M | $-468.10M | $1.10B | $1.84B | $1.21B |
Biogen Dividends
Explore Biogen's dividend history, including dividend yield, payout ratio, and historical payments.
Biogen News
Read the latest news about Biogen, including recent articles, headlines, and updates.
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4 * ) non-carriers or heterozygotes with confirmed amyloid pathology
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline, despite the market's current undervaluation. Sage's Zuranolone shows strong market traction in PPD, with significant insurance coverage and increasing prescriptions, indicating future growth potential.
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen's presence in Kendall Square, integrating Biogen's research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stifel Paul Matteis Great. Good morning, everybody.
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen's total revenues declined 2% in 2024.
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR). TRANSCEND is designed to enroll approximately 120 kidney transplant recipients with late AMR.
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ET Company Participants Alisha Alaimo - President of North America Conference Call Participants Marc Goodman - Leerink Partners Marc Goodman Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here, Alisha Alaimo, who is the President of North America.
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 45th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen.
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52.
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mirroring Aduhelm's failure, and Biogen's pipeline lacks promising products to drive future growth. The multiple sclerosis franchise is in decline, and new drug approvals like Qalsody and Skyclarys have shown minimal revenue impact.
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Conference Call Participants Salveen Richter - Goldman Sachs Michael Yee - Jefferies Tim Anderson - Bank of America Brian Abrahams - RBC Capital Markets Marc Goodman - Leerink Paul Matteis - Stifel Umer Raffat - Evercore ISI Chris Schott - JPMorgan Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Operator Good morning. My name is Jennifer and I will be your conference operator today.
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for BIIB.